Alcobra (ADHD) Announces Quarterly Results
Alcobra (NASDAQ:ADHD) issued its quarterly earnings data on Thursday. The company reported ($0.57) EPS for the quarter, AnalystRatings.Net reports.
Alcobra (NASDAQ:ADHD) opened at 16.10 on Thursday. Alcobra has a one year low of $6.50 and a one year high of $26.96. The stock has a 50-day moving average of $16.91 and a 200-day moving average of $18.79. The company’s market cap is $219.5 million.
ADHD has been the subject of a number of recent research reports. Analysts at Canaccord Genuity initiated coverage on shares of Alcobra in a research note on Thursday, April 17th. They set a “buy” rating and a $24.00 price target on the stock. Analysts at JMP Securities initiated coverage on shares of Alcobra in a research note on Thursday, March 6th. They set an “outperform” rating and a $36.00 price target on the stock.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.